Renal Cell Cancer, Recurrent Completed Phase 1 / 2 Trials for Fludeoxyglucose (DB15107)

Also known as: Recurrent Renal Cell Cancer

IndicationStatusPhase
DBCOND0082537 (Renal Cell Cancer, Recurrent)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT0180667518F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis TherapyDiagnostic